 The MMPREDICT study is a Horizon 2020 project started in November 2016 and is funded by the European Commission on the Horizon 2020 program. It is a team of two clinical partners. We have the Erasmus Medical Center and the University of Turin. We have a biotech company, Scott and the X. We have the Erasmus University, the economic partner within our team. And we have the Miloma Patients Europe as a partner representative in the project. We aim to develop a diagnostic tool which can predict the most effective treatment for each Miloma patient. Scott and the X is a specialized company in the development and validation of diagnostic tests. We have put already a test on the market for Miloma, the MMPREDICT. And it's a test which can distinguish patients from in a high risk group or a standard risk group. Currently we're now focusing more on the treatment side. If we can also predict which treatment is best for which patients and that's where we can implement our knowledge in the development of such tests. So we will measure genetic information from different multiple Miloma patients throughout Europe. We have recruited 800 patient samples and we hope to get some genetic information and from these patients look at their treatment and see if there's any correlation between those. In that sense we can implement this in the future to predict which patients is most suitable for which treatment. We hope that every patients get the optimal treatment they deserve and in that sense focus on the most effective treatment for each individual Miloma patients. Also we hope to provide this and improve the care of these patients so reduce the side effect and directly get the right treatment for these patients. Pervasmus University is involved in looking at the economic and the patient benefits of different ways to treat patients with multiple Miloma. I think in general everybody believes that personalized medicine will benefit patients and should it perhaps also help us to keep the costs low, the costs of healthcare going up and we have to find ways to make sure that we use our money well. So that I think is the main benefit. The main challenge is how we combine all the different bits of information in order to know for sure how to treat everybody in the best way possible. I think that we are bringing together different areas of expertise in order to understand what's going on with patients now and how can we treat patients better in the future. The survey is mainly looking at the current quality of care and quality of life that the patients experience in different European countries. Well what we're going to do is include the results from that survey in the analyses in the future. Now analyses that will help us work out what the impact would be if we personalize care and how much we can improve quality of life. That patients it will be treated better than they are now using newer medicines that are becoming available but ensuring that they're only going to get those medicines if those medicines will really work with them. Pognito is a partner of this European project and is contributing to the project with the recruitment of patient samples and patient information. Diagnosis or at relapse patients perform a bone marrow aspirator or bone marrow biopsy and through the iliac spine and this sample is used for diagnosis of the disease and then can be stored through a freezing procedure in our lab, in our institution. I hope that this project will develop a tool, a predictive tool able to identify the more effective therapy for each individual patient.